Empire Genomics LLC of Buffalo will expand its prostate testing capabilities after acquiring the exclusive license to technology from Cornell University.
The company is developing a molecular diagnostic test using a patent-pending genomic biomarker licensed from Cornell. The test could help in the diagnosis and treatment for patients with neuroendocrine prostate cancer (NEPC).
Patients diagnosed with this form of cancer most often die within a year of diagnosis, and there are currently no effective therapies.
Company officials said Empire Genomics will launch a genetic test later this year to diagnose NEPC. Company executives hope to partner with a pharmaceutical company to use the test to more quickly identify which patients develop this form of cancer during clinical trials.
Based on the Buffalo Niagara Medical Campus, the company offers molecular genomic testing with a specialization in oncology and personalized medicine.